Methotrexate PBPK model examines pediatric extrapolation, drug interactions, and renal impairment
Academic source · Scientific Reports
Source published:
Site published: 2026-11-08 · Updated: 2026-11-08
This source is linked automatically. Choose a question to get started.
What the paper reports
A Scientific Reports study developed a whole-body model of methotrexate and its metabolite using adult and pediatric pharmacokinetic profiles. Predicted exposure measures were generally within twofold of observed values. Simulations examined five interacting drugs and indicated increased exposure with renal impairment at high doses. These are model-based assessments, not prospective evidence that a dosing regimen improves clinical outcomes.
Why this paper is included
Potential business implication: a reusable parent-metabolite model may support pediatric development and interaction-risk assessment, with scenario-specific qualification still needed.
The interpretation above is analysis, not a conclusion attributed to the original source.
Read the original source ↗Prepared through Biotech Assistant’s automated research workflow. Editorial standards and corrections